Navigation Links
HDSA Applauds Announcement of the First Therapy to be Approved for the Specific Treatment of a Symptom of Huntington's Disease
Date:8/15/2008

NEW YORK, Aug. 15 /PRNewswire/ -- The approval of Xenazine(R) (tetrabenazine), for the treatment of chorea associated with Huntington's Disease (HD), the first therapy to be approved specifically for the disease, is a significant milestone for all of our patients, families and caregivers in the HD community. Huntington's Disease Society of America (HDSA) is very pleased that we have the first treatment to alleviate one of the symptoms of this devastating disease.

"This is a great moment for our families, who have been waiting for answers to HD for a long time," said Barbara Boyle, National Executive Director/CEO of HDSA. "Our families should be proud that their advocacy efforts helped make a difference. We thank the developers of Xenazine for their work and perseverance, and look forward to more announcements of therapeutic approvals by the FDA in the near future. We will provide information on the future availability of Xenazine on our website (http://www.hdsa.org), and in our electronic and print publications as soon as details are provided to HDSA."

Huntington's Disease is a devastating, hereditary, degenerative brain disorder for which there is, at present, no effective treatment or cure. HD slowly diminishes the affected individual's ability to walk, think, talk and reason. Eventually, the person with HD becomes totally dependent upon others for his or her care. Huntington's Disease profoundly affects the lives of entire families -- emotionally, socially and economically. More than a quarter of a million Americans have HD or are "at risk" of inheriting the disease from an affected parent. HD affects as many people as Hemophilia, Cystic Fibrosis or ALS.

Early symptoms of Huntington's Disease may affect cognitive ability or mobility and include depression, mood swings, forgetfulness, clumsiness, involuntary twitching and lack of coordination. As the disease progresses, concentration and short-term memory diminish and involuntary movements of the head, trunk and limbs increase. Walking, speaking and swallowing abilities deteriorate. Eventually the person is unable to care for him or herself. Death follows from complications such as choking, infection or heart failure.

HD typically begins in mid-life, between the ages of 30 and 50, though onset may occur as early as the age of 2. Children who develop the juvenile form of the disease rarely live to adulthood.

HD affects males and females equally and crosses all ethnic and racial boundaries. Each child of a person with HD has a 50/50 chance of inheriting the fatal gene. Everyone who carries the gene will develop the disease. For more information please visit our website, http://www.hdsa.org, or contact us at (800)-345-HDSA or hdsainfo@hdsa.org.


'/>"/>
SOURCE Huntington's Disease Society of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AIDS Action Committee Applauds Legislature for Taking Action to Protect Patient Privacy Within New Electronic Medical Records System
2. AMA Applauds U.S. House for Acting to Protect Americans From the Dangers of Tobacco
3. CMMB Applauds America at Its Best as PEPFAR is Reauthorized by U.S. Government
4. AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs
5. APHA Applauds Congressional Override of Medicare Veto
6. American Optometric Association Applauds Override of Medicare Cuts
7. ACP applauds Senate to vote to pass H.R. 6331 and avert physician payment cut
8. American Life League Applauds Congressional Action Against Planned Parenthood
9. NCOA Applauds Senate Passage of Medicare Bill
10. Kidney Community Applauds Senate for Passage of End Stage Renal Disease (ESRD) Improvements
11. Tubbs Jones Applauds Senate Passage of Medicare Improvements Bill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance Company ... life insurance throughout various life stages. , The site launched on April 1, ... and content specific to the times when life insurance matters most. , “Through ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident Matching Program® ... Match® (“the Match”), the system through which U.S. and international medical school students ... positions were placed in the 2016 Match, and 29,572 were filled when the ...
(Date:5/2/2016)... NY (PRWEB) , ... May 02, 2016 , ... Over ... the year’s best in pet gear and toys, leading product review site for Toys, ... Paw of Excellence Awards at their Spring Showcase at the Metropolitan Pavilion in ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
Breaking Medicine Technology: